2023 World Conference on Lung Cancer (Posters)-P2.06. Phase I/II Study of Rucaparib and Pembrolizumab Maintenance in Stage IV NSCLC after Carboplatin, Pemetrexed, Pembrolizumab

P2.06. Phase I/II Study of Rucaparib and Pembrolizumab Maintenance in Stage IV NSCLC after Carboplatin, Pemetrexed, Pembrolizumab - PDF(Slides)

Back to course

Pdf Summary

This document reports on a phase I/II multi-site study investigating the potential benefits of maintenance therapy with the PARP inhibitor rucaparib and the PD-1 inhibitor pembrolizumab in stage IV non-squamous non-small cell lung cancer (NSCLC) patients. The study enrolled patients who had initially received treatment with carboplatin, pemetrexed, and pembrolizumab. The hypothesis was that the combination of a PARP inhibitor and pembrolizumab would improve progression-free survival (PFS) compared to standard maintenance therapy with pemetrexed and pembrolizumab.<br /><br />The preliminary findings showed that patients who received rucaparib and pembrolizumab maintenance therapy had a numerically longer PFS and overall survival (OS) compared to patients who did not receive this maintenance therapy. These differences were statistically significant for OS. The safety profile of the combination therapy was generally well-tolerated, with fatigue and nausea being the most frequent adverse events.<br /><br />The study authors highlight that this is the first study to examine a switch maintenance therapy in stage IV non-squamous NSCLC. They note that the results are encouraging and suggest that maintenance therapy with a PARP inhibitor and PD-1 inhibitor should be further explored in larger, randomized studies.<br /><br />Overall, this study suggests that the combination of rucaparib and pembrolizumab as maintenance therapy may provide improved outcomes for patients with stage IV non-squamous NSCLC. However, further research is needed to confirm these findings and evaluate the efficacy and safety of this combination in larger patient populations. This study was funded by Merck and Clovis, and the authors acknowledge the support of the patients, their families, and the study teams at the participating institutions.

Asset Subtitle

Angel Qin

Meta Tag

Speaker Angel Qin

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

phase I/II

multi-site study

maintenance therapy

PARP inhibitor

rucaparib

PD-1 inhibitor

pembrolizumab

stage IV non-squamous non-small cell lung cancer

progression-free survival

overall survival